News
The study by the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT) research group (May 19 issue) 1 supports off-label use of bevacizumab (Avastin) for neovascular age-related ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback